Drug Information

Drug General Information
Drug ID
D04VBF
Former ID
DIB015670
Drug Name
JNJ-38518168
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2 [525005]
Company
Janssen research & development
Structure
Download
2D MOL

3D MOL
Canonical SMILES
CN1CCC(CCCNc2ncc(c(C)n2)c3nc4c(C)cc(C)cc4[nH]3)CC1
InChI
1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
InChIKey
FCRFVPZAXGJLPW-UHFFFAOYSA-N
Target and Pathway
Target(s) Histamine H4 receptor Target Info Antagonist [544472]
KEGG Pathway Neuroactive ligand-receptor interaction
Reactome Histamine receptors
G alpha (i) signalling events
WikiPathways GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 525005ClinicalTrials.gov (NCT02295865) A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis. U.S. National Institutes of Health.
Ref 544472The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.